Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study
Top Cited Papers
- 15 September 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 98 (6) , 1760-1764
- https://doi.org/10.1182/blood.v98.6.1760
Abstract
The pathogenetic role and the clinical importance of the presence of antiphospholipid antibodies (APAs) in patients with immune thrombocytopenic purpura (ITP) are not clear. In this study, the prevalence and clinical significance of APAs were investigated in patients with ITP. Eighty-two newly diagnosed ITP patients were prospectively studied. They were evaluated for the presence of lupus anticoagulant (LA) and immunoglobulin G/M anticardiolipin antibodies (ACAs). Thirty-one patients (37.8%) were APA positive at diagnosis. No statistically significant differences were found between the APA-positive and APA-negative groups regarding gender, initial platelet counts, or response to methylprednisolone therapy. After 5 years of follow-up, cumulative thrombosis-free survival of APA-positive (n = 31) and APA-negative (n = 51) ITP patients was 39% and 97.7%, respectively. A significant difference was found between these groups by log-rank test (P = .0004). In addition, LA was an important risk marker for the development of thrombosis in ITP patients. After a median follow-up of 38 months, 14 ITP patients (45%) who had APA positivity developed clinical features (thrombosis or fetal losses) of antiphospholipid syndrome (APS). There were no differences between the APA-positive patients with and without APS regarding the initial platelet counts, response to the therapy, or ACA positivity. The positivity rate for LA was significantly higher in those patients with ITP who developed APS (χ2: P = .0036; relative risk 7.15; 95% confidence interval, 1.7-47). In conclusion, this study indicates that a significant proportion of patients initially presenting with ITP and APA positivity developed APS. In patients with ITP, the persistent presence of APAs is an important risk factor for the development of APS.Keywords
This publication has 18 references indexed in Scilit:
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- The Risk of Thrombosis in Patients with Lupus Anticoagulants Is Predicted by their Specific Coagulation ProfileThrombosis and Haemostasis, 1999
- Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopeniaEuropean Journal of Haematology, 1998
- Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndromeBritish Journal of Haematology, 1997
- Anti‐platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopeniaBritish Journal of Haematology, 1997
- Thrombocytopenia in the antiphospholipid syndromeBritish Journal of Haematology, 1996
- Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpuraThe American Journal of Medicine, 1995
- Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopeniaEuropean Journal of Haematology, 1994
- The Second International Anti-Cardiolipin Standardization Workshop/The Kingston Anti-Phospholipid Antibody Study (KAPS) GroupAmerican Journal of Clinical Pathology, 1990
- Anticardiolipin antibodies in autoimmune thrombocytopenic purpuraBritish Journal of Haematology, 1985